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Ttm purpose of this study was to evaluate whether
nedocromil sodium benefits urban asthmatic children
showing seasonal bronchial hyper-reactivity to ultra-
sonic nebulization of distilled water (UNDW). A prospec-
tive, randomized, placebo-controlled, parallel-group,
double-blind study was carried out at the outpatient
pulmonology service at a tertiary-care teaching hospital.
Twelve children Hving in Milan, who were 7-17 years of
age, who were SPT and RAST-negative to perennial aller-
gens, who were suffering from episodic asthma, and
showing seasonal bronchial hyper-reactivity to UNDW
during winter, participated in this study. All the children
received either placebo or nedocromil sodium, 4 mg
every 6 h for 6 weeks. Spirometry and UNDW challenge
were done at the following times: day-7; day 0; day 1; day
7; day 14; day 28; day 42. No differences were found in
the basal spirometric parameters, which were normal in
both nedocromil and placebo groups. Bronchial reactiv-
ity to UNDW was found to be significantly decreased in
the group treated with nedocromtl starting from day 7. It
is therefore concluded that nedocromil sodium can re-
verse bronchial hyper-reactivity caused by seasonal fac-
tors such as cold, viral infections and atmospheric pollut-
ants in children suffering from asthma.
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Introduction
Bronchial hyper-reactivity (i.e. exaggerated
bronchoconstrictive response to various stimuli) is a
characteristic of asthma both in children and adults. 1,"
Bronchial hyper-reactivity is, in part, genetically de-
termined and, in part, a consequence of airway
inflammation, and it is closely related to the sever-
ity of the disease. Studies performed on animal
models show that exposure to such environmental
pollutants as SO4 and ozone may induce bronchial
hyper-reactivity, and it has been suggested that cli-
mate-therapy may attenuate these effects.9,1 In chil-
dren living in urban areas, exposure to pollution has
been associated with an increase in the number of
cases of secretive chronic bronchitis and to a reduc-
tion in respiratory function,
11 as well as to an increase
in asthma1" and to a higher risk of allergic
sensitization.
Anti-inflammatory drugs, such as inhaled
corticosteroids and cromones, are widely used to
reverse bronchial hyper-reactivity. 14-2 The aim of this
study was to evaluate the protective effect of
nedocromil sodium on bronchial hyper-reactivi.ty in
a group of non-atopic asthmatic children who were
showing seasonal bronchoreactivity, and who were
living in town.
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Patients and Methods
From 1 November to 31 December 1990, children
attending the Allergology and Pneumology Out-Pa-
tients Clinic of the 5th Pediatric Department of the
University of Milan were recruited according to the
following criteria: age 6-18 years; suffering from
bronchial asthma; living and attending school in
Milan; skin tests and RAST negative for perennial
allergens (house dusts, dermatophagoides, animal
dander); seasonal bronchoreactivity, assessed as: (1)
positive aspecific challenge to ultrasonic mist per-
formed between 1 October 1989 and 31 March 1990
(time A); (2) negative challenge performed between
1 August and 30 September 1990 (time B); and (3)
positive challenge performed upon recruitment
(time C).
Exclusion criteria were: non-response to challenge
with ultrasonic nebulized distilled water (UNDW) at
time A or C; response to challenge with UNDW at
time B; positive skin tests for perennial inhalant
allergens; airway infection within 30 days of the tests;
intake of ]3-2 agonists, theophylline, cromones,
corticosteroids, antihistamines and ketotyphen, 6 h
before testing. The relevant features of the patients
of the two groups are shown in Table 1.
Patients inhaled UNDW, 5 ml/min per 5 min,
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Table 1. Relevant features of the patients of the two groups
Group N Group P
Patient Sex Age Weight Height Patient Sex
(yrs) (kg) (cm)
Age Weight Height
(yrs) (kg) (cm)
M 7.5 22 126 2 M 16.2 67 181
3 M 12.4 45 152 6 M 15.7 68 185
4 M 11.7 40 156 7 M 7.1 27 125
5 F 9.1 30 132 8 M 14.1 54 173
9 F 8.1 32 134 11 M 12.3 50 159
10 F 13.2 53 159
12 M 11.7 37 149
delivered by a Fujikogaru ultrasonic nebulizer
(Osaka, Japan) that produces 5 I.tm particles of water.
UNDW was administered according to Allegra and
Bianco. 21 A test was judged positive when after chal-
lenge FEV1 (forced expiratory volume in l s)
dropped 20% or more, and/or MMEF (maximal mid-
expiratory flow) dropped 35% or more. Spirometric
evaluations and flow/volume curve recordings were
always performed at the same time (14.00-16.00 h),
6 h after the last administration of nedocromil, using
a Spirostar FG 90 spirometer (Werner-Gut AG, Bern,
CH), equipped with a n.2 Fleisch pneumo-
tachograph; reference parameters were according
to Zapletal.
2" Before challenge, a basal spiro-
metric examination was performed, and measure-
ments were taken at 1, 2, 5, 10 and 15 min after the
challenge. Fourteen children fulfilling the above-
listed criteria were included in this trial. The subjects
were nine males and five females, aged 7.33-16.92
years (mean age: 10.12 _+ 3.52 years; median age:
11.40 years). After informed consent was obtained,
children were randomly assigned to treatment with
nedocromil sodium, 2 puffs four times per day for 42
days (group N; seven subjects), or to the placebo
group (group P).
In case of asthmatic episodes, salbutamol could be
taken (Ventolin MDI, Glaxo, Verona, Italy), at a dose
of 1 puff, corresponding to 200 btg, up to four times
daily.
Cromones, corticosteroids and antihistamines
were not allowed throughout the study period.
Aspecific challenge by inhalation of UNDW was
performed at the following times: -7 days (time-7);
day 0 (time 0); day 1 (time 1); day 7 (time 7); day 14
(time 14); day 28 (time 28); day 42 (time 42). Data are
expressed in percentages with respect to expected
values, according to the formula:
measured value
x 100
expected value
The results of the aspecific bronchoreactivity test
are expressed in percentages with respect to baseline
as follows:
baseline- post-challenge value
baseline
x 100
Evaluation was performed with Mann-Whitney’s
non parametric tests, and Wilcoxon’s rank-sum test.
Results
Two girls of group P dropped out of the study; one
because of an airway infection, probably caused by
a virus, and the other because of an asthma attack
that was treated with systemic steroid. The data of
these two subjects were not included in the final
evaluation. Therefore, 12 children completed the
study: nine male and three female, aged 7.33-16.92
years (mean age: 11.86 _+ 2.04 years; median age:
12.20 years). Seven subjects (four male and three
female; aged 7.42-13.42 years; mean age. 10.81 +
2.16 years; median age. 11.33 years) belonged to
group N, and five males constituted group P (age
7.33-16.92 years; mean age: 13.33 -+ 3.71 years; me-
dian age: 14.42 years). No significant age-related
difference was found between the two groups (f
2.23; t 1.49; p N.S.).
Basal spirometricparameters (baseline As
shown in Fig. 1, there was no difference at any time
for VC (vital capacity; baseline/expected), PEF (peak
expiratory flow), FEV1 and FEF25-75 (forced expira-
tory flow between 25 and 75% of vital capacity)
between the treated and placebo groups. The data
show a parallel trend which was fairly constant in
time; therefore, nedocromil sodium treatment did not
affect the parameters measured.
Bronchoreactivoty to challenge with UNDW: Fig 2
shows the median percentage variations (UNDW/
baseline) of vital capacity, FEV1, PEF, and FEF25-75
in the treated and in the placebo group. The change
in vital capacity after UNDW was substantially less in
the treated group, even before therapy (t -7), but
the difference became significant during treatment
(Table 2). At day-7, FEV1 changes afterUNDW were
similar in the two groups. Differences were observed
at day 7: bronchoreactivity in the placebo group
remained stable, and decreased significantly in the
treated group (Table 3).
The profile of PEF after UNDW was almost parallel
in the two groups; only at day 42 was there a
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FIG. 1. Spirometric parameters at baseline in treated and placebo group (percentage of expected value): p N.S. at any time.
Table 2. Median _
SE and percentage of vital capacity (after
UNDW/baseline) in groups N and P at different times
Time Group N Group P p
-7 92.5 + 1.25 89.9 + 3.04 0.12
0 90.7 + 0.66 88.9 + 2.97 0.14
96.4 + 0.79 94.5 + 2.05 0.02
7 95.4 + 4.25 91.1 + 1.62 0.12
14 95.1 + 1.40 87.6 + 2.38 0.02
28 94.8 + 1.30 86.7 + 3.42 0.04
42 96.4 + 1.42 87.6 + 1.89 0.01
Table 3. Median _+ SE and percentage of FEV1 (after UNDW/
baseline) in groups N and P at different times
Time Group N Group P p
-7 74.2 + 0.94 76.1 + 2.58 0.80
0 75.8 + 0.83 75.4 + 1.03 0.80
79.0 + 1.02 77.1 + 2.06 0.37
7 85.2 + 1.39 74.2 + 0.95 0.01
14 90.6 + 1.04 76.7 + 1.11 0.004
28 90.5 + 2.73 76.7 + 3.50 0.06
42 92.8 + 0.97 76.0 + 0.77 0.004
significant decrease in bronchoreactivity in group N
(Table 4). FEF 25-75 changes after UNDW, which
were initially comparable, showed a progressive
decrease in bronchoreactivity in group N, and no
change in group P (Table 5).
Discussion
Although changes in bronchial reactivity have
been reported in adult and young asthmatic patients,
few attempts have been made to identiy the cause
of this behaviour. In allergic children, bronchial re-
activity may increase during the season of exposure
to the allergen. 14,15 Children affected by episodic
asthma or by seasonal, non-atopic, recurrent asthma,
whose hyper-reactivity was seasonal (i.e. it appeared
in winter and disappeared in summer) were studied.
In these cases, alteration in reactivity may reflect an
inflammatory process induced, in winter, by such
Table 4. Median + SE and percentage 6f PEF (after UNDW/
baseline) in groups N and P at different times
Table 5. Median _+ SE and percentage of FEF 25-75 (after UNDW/
baseline) in groups N and P at different times
Time Group N Group P p Time Group N Group P p
-7 75.3 + 2.52 78.9 + 3.73
0 77.0 + 1.95 77.1 + 1.94
80.0 + 4.20 82.5 + 4.03
7 78.6 + 2.65 74.3 + 2.73
14 86.1 + 2.09 73.5 + 4.76
28 82.1 + 2.37 79.7 + 2.62
42 86.4 + 2.13 72.9 + 2.32
0.68
0.68
0.80
0.16
0.12
0.29
0.01
-7 75.5 + 7.21 72.4 + 6.71 0.80
0 75.2 + 4.98 79.3 + 4.17 0.56
82.4 + 3.68 79.4 + 6.29 0.46
7 83.7 + 1.29 76.6 + 6.57 0.02
14 83.9 + 2.39 70.1 + 5.36 0.04
28 83.9 + 2.10 75.9 + 3.07 0.02
42 90.9 + 4.24 73.5 + 6.95 0.16
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FIG. 2. Spirometric parameters after UNDW challenge in treated and placebo group (percentage of pre-challenge value): for significance, see Tables 2-5.
factors as cold, exposure to viral infection, and at-
mospheric pollutants. These patients, who were
somewhat rare, were selected in order to test the
efficacy of nedocromil sodium in extrinsic non-aller-
gic asthma.
The results of .this study indicate that nedocromil
sodium was beneficial in these patients. From the
second week of treatment, patients showed a better
spirometric performance, and maintained good clini-
cal conditions. Despite the small number of subjects
and the relatively short study period, the data are
statistically significant: this confirms the efficacy of
nedocromil sodium as a prophylactic treatment.
No difference in functional parameters was found
between the two groups in baseline conditions, but
there was a progressive improvement in the values of
the N group measured after UNDW. This is consistent
with clinical data and recruitment criteria (i.e. chil-
dren with episodic asthma, whose resting respiratory
function was very close to normal); functional disor-
ders only occurred after aspecific challenge. To our
knowledge, our data are the first to show that
nedocromil sodium affords protection against
UNDW challenge in asthmatic children.
Our results are consistent with previous reports of
preadministration of 2 and 4 mg of nedocromil so-
dium, 10-30 min before aspecific challenge prevents
bronchospasm induced by UNDW. 17 However, we
performed the test at least 6 h after administration of
S46 Mediators of Inflammation. Vol 3 (Supplement). 1994
nedocromil sodium; therefore, the effect obtained
cannot be attributed to an immediate inhibition, but
rather to a reduction in the airway inflammation
underlying the hyper-reactivity. Nedocromil sodium
is known to exhibit a series of anti-inflammatory
activities: it prevents the generation of neutrophil
chemotactic peptides as IL-8,’3 inhibits human
neutrophil chemotaxis,’<’5 decreases the broncho-
spastic response induced by SO,. inhalation in animal
models,’6 and prevents infiltration of neutrophils
from bronchial mucosa of dogs exposed to ozone.8
Recent findings suggest that nedocromil sodium
downregulates activation of cells involved in the late-
phase asthmatic reaction, such as eosinophils,’7 mast-
cells and T-cells.28 Although it inhibits the develop-
ment of mucosal inflammation, it was uncertain
whether nedocromil sodium eliminates or reduces
existing inflammatory changes. ’9 Our data suggest
that it can do this, as clinical trials have demonstrated
its efficacy in diminishing the late phase asthmatic
reaction. Therefore, the drug not only prevents the
seasonal increase in aspecific bronchial reactivity as
previously reported in patients naturally exposed to
allergens, 15,16 but it is also useful in the treatment of
non-allergic asthma.
In conclusion, nedocromil sodium, which may be
used as prophylaxis in atopic asthmatic subjects with
symptoms and bronchial hyper-reactivity upon natu-
ral exposure to allergens, may also be used to treatEffect of nedocromil on aspecific bronchial hyper-reactivity
children suffering from episodic asthma, in whom
airway inflammation increases bronchial reactivity.
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